Description
DARPA seeks innovative research proposals to create a universal, software‑defined platform that can precisely edit endogenous proteins in living cells and tissues without altering the genome. The effort is organized into three phases (Base Phase 1A – 18 months, Option 1 Phase 1B – 6 months, and Phase 2 – 18 months) and requires demonstrable advances in programmable targeting, generalizable chemistry, and multiplexed editing across multiple protein families, with validation in organoids and animal models. The award will be an Other Transaction Agreement (OTA) prototype, with mandatory CUI compliance and CMMC Level 1 by the end of Phase 1A, and includes optional student‑funding streams (FDRTA and IIP).
• Develop de‑novo binders and editing chemistries that work on at least three distinct protein structural families (globular, transmembrane, fibrous).
• Demonstrate multiplexed, orthogonal protein edits in high‑fidelity cellular models (organoids) and later in animal systems.
• Deliver a complete prototype, data packages, and a transition‑ready go‑to‑market plan by month 42, with fixed‑payable milestones tied to technical demonstrations.